223 related articles for article (PubMed ID: 18215180)
1. Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle.
Grounds MD; Radley HG; Gebski BL; Bogoyevitch MA; Shavlakadze T
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):846-51. PubMed ID: 18215180
[TBL] [Abstract][Full Text] [Related]
2. Waste management - cytokines, growth factors and cachexia.
Saini A; Al-Shanti N; Stewart CE
Cytokine Growth Factor Rev; 2006 Dec; 17(6):475-86. PubMed ID: 17118696
[TBL] [Abstract][Full Text] [Related]
3. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice.
Hodgetts S; Radley H; Davies M; Grounds MD
Neuromuscul Disord; 2006 Oct; 16(9-10):591-602. PubMed ID: 16935507
[TBL] [Abstract][Full Text] [Related]
4. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice.
Radley HG; Grounds MD
Neurobiol Dis; 2006 Aug; 23(2):387-97. PubMed ID: 16798005
[TBL] [Abstract][Full Text] [Related]
5. Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice.
Piers AT; Lavin T; Radley-Crabb HG; Bakker AJ; Grounds MD; Pinniger GJ
Neuromuscul Disord; 2011 Feb; 21(2):132-41. PubMed ID: 21055937
[TBL] [Abstract][Full Text] [Related]
6. Beneficial synergistic interactions of TNF-alpha and IL-6 in C2 skeletal myoblasts--potential cross-talk with IGF system.
Al-Shanti N; Saini A; Faulkner SH; Stewart CE
Growth Factors; 2008 Apr; 26(2):61-73. PubMed ID: 18428025
[TBL] [Abstract][Full Text] [Related]
7. Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment.
Radley HG; Davies MJ; Grounds MD
Neuromuscul Disord; 2008 Mar; 18(3):227-38. PubMed ID: 18207402
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage.
Gehrig SM; Ryall JG; Schertzer JD; Lynch GS
Exp Physiol; 2008 Nov; 93(11):1190-8. PubMed ID: 18567600
[TBL] [Abstract][Full Text] [Related]
9. Role of IGF-I in skeletal muscle mass maintenance.
Clemmons DR
Trends Endocrinol Metab; 2009 Sep; 20(7):349-56. PubMed ID: 19729319
[TBL] [Abstract][Full Text] [Related]
10. A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo.
Shavlakadze T; Chai J; Maley K; Cozens G; Grounds G; Winn N; Rosenthal N; Grounds MD
J Cell Sci; 2010 Mar; 123(Pt 6):960-71. PubMed ID: 20179101
[TBL] [Abstract][Full Text] [Related]
11. Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulinlike growth factor-I in chronic heart failure.
Schulze PC; Gielen S; Adams V; Linke A; Möbius-Winkler S; Erbs S; Kratzsch J; Hambrecht R; Schuler G
Basic Res Cardiol; 2003 Jul; 98(4):267-74. PubMed ID: 12835956
[TBL] [Abstract][Full Text] [Related]
12. Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy.
Philippou A; Halapas A; Maridaki M; Koutsilieris M
J Musculoskelet Neuronal Interact; 2007; 7(3):208-18. PubMed ID: 17947802
[TBL] [Abstract][Full Text] [Related]
13. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice.
Shavlakadze T; White J; Hoh JF; Rosenthal N; Grounds MD
Mol Ther; 2004 Nov; 10(5):829-43. PubMed ID: 15509501
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-1 in myocardial tissue: interaction with tumor necrosis factor.
Wang M; Tsai B; Brown JW; Meldrum DR
Crit Care; 2003 Dec; 7(6):417-9. PubMed ID: 14624679
[TBL] [Abstract][Full Text] [Related]
15. Isolation and validation of human prepubertal skeletal muscle cells: maturation and metabolic effects of IGF-I, IGFBP-3 and TNFalpha.
Grohmann M; Foulstone E; Welsh G; Holly J; Shield J; Crowne E; Stewart C
J Physiol; 2005 Oct; 568(Pt 1):229-42. PubMed ID: 16081485
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis.
Grounds MD; Torrisi J
FASEB J; 2004 Apr; 18(6):676-82. PubMed ID: 15054089
[TBL] [Abstract][Full Text] [Related]
17. Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice.
Gregorevic P; Plant DR; Lynch GS
Muscle Nerve; 2004 Sep; 30(3):295-304. PubMed ID: 15318340
[TBL] [Abstract][Full Text] [Related]
18. Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro.
Philippou A; Papageorgiou E; Bogdanis G; Halapas A; Sourla A; Maridaki M; Pissimissis N; Koutsilieris M
In Vivo; 2009; 23(4):567-75. PubMed ID: 19567392
[TBL] [Abstract][Full Text] [Related]
19. Pro- and anti-apoptotic roles for IGF-I in TNF-alpha-induced apoptosis: a MAP kinase mediated mechanism.
Saini A; Al-Shanti N; Faulkner SH; Stewart CE
Growth Factors; 2008 Oct; 26(5):239-53. PubMed ID: 18651291
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor I signaling in skeletal muscle and the potential for cytokine interactions.
Adams GR
Med Sci Sports Exerc; 2010 Jan; 42(1):50-7. PubMed ID: 20010130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
